Skip to main content
Premium Trial:

Request an Annual Quote

USPTO to Re-examine Two Patents in Affymetrix, Illumina Litigation

NEW YORK (GenomeWeb News) – Illumina said today that the US Patent and Trademark Office has ordered a re-examination of two patents at the heart of ongoing intellectual property litigation between the firm and Affymetrix.
 
The two patents being re-examined are No. 6,355,432, entitled “Products for detecting nucleic acids,” and No. 6,646,243, entitled “Nucleic acid reading and analysis system.”
 
Both patents are assigned to Affymetrix and are part of Affy’s patent infringement suit filed against Illumina in July 2004 in the US District Court for the District of Delaware.
 
In March, a jury sided with Affy in the first phase of the litigation. It found that Illumina's arrays, assays, scanners, software, and related products infringe “one or more claims” of all five of the patents Affy mentioned in the suit.
 
The jury awarded total damages of more than $16.7 million for the period of 2002-2005 and imposed a royalty of 15 percent.
 
The next phase of that case will focus on the validity of Affymetrix's patents and is scheduled to begin on Feb. 11, 2008. The following phase is expected to occur in May or June 2008 and will determine whether Illumina's infringement was willful.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.